Literature DB >> 10395884

Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

R Lira1, S Sundar, A Makharia, R Kenney, A Gam, E Saraiva, D Sacks.   

Abstract

The possibility that the high frequency of treatment failures in Indian kala-azar might be due to infection with antimony-resistant strains of Leishmania donovani has not been experimentally addressed. L. donovani isolates were obtained from splenic aspiration smears of 24 patients in Bihar, India, who either did not respond (15) or did respond (9) to 1 or more full courses of treatment with sodium antimony gluconate (SAG). A strong correlation (P<.001) between clinical response and SAG sensitivity in vitro was observed only when strains were assayed as intracellular amastigotes: responsive isolates ED50=2.4+/-2.6, ED90=6.4+/-7.8 microgram SAG/mL; unresponsive isolates ED50=7.4+/-3.7 microgram SAG/mL, ED90=29.1+/-11.1 SAG/mL. No correlation with clinical response was found by use of extracellular promastigotes (ED50=48+/-22 vs. 52+/-29 microgram/mL). The emergence of antimony-resistant L. donovani strains appears to be a cause of treatment failures in India.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395884     DOI: 10.1086/314896

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  124 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters.

Authors:  Chiranjib Pal; Mousumi Raha; Anirban Basu; Keshab Chandra Roy; Anasuya Gupta; Monidipa Ghosh; Niranjan Prasad Sahu; Sukdeb Banerjee; Nirup Bikash Mandal; Santu Bandyopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Studies on stibanate unresponsive isolates of Leishmania donovani.

Authors:  Anindita Bhattacharyya; Mandira Mukherjee; Swadesh Duttagupta
Journal:  J Biosci       Date:  2002-09       Impact factor: 1.826

4.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

5.  In vitro antileishmanial and antitrypanosomal activities of five medicinal plants from Burkina Faso.

Authors:  W R Sawadogo; G Le Douaron; A Maciuk; C Bories; P M Loiseau; B Figadère; I P Guissou; O G Nacoulma
Journal:  Parasitol Res       Date:  2011-10-25       Impact factor: 2.289

6.  Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Authors:  Dhiraj Kumar; Ruchi Singh; Vasundhra Bhandari; Arpita Kulshrestha; Narendra Singh Negi; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

7.  Downregulation of mitogen-activated protein kinase 1 of Leishmania donovani field isolates is associated with antimony resistance.

Authors:  Mansi Garg; Shyam Sundar; Robert Duncan; Hira L Nakhasi; Neena Goyal
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

8.  Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

Authors:  Prabhat K Sinha; Paul Roddy; Pedro Pablo Palma; Alice Kociejowski; María Angeles Lima; Vidya Nand Rabi Das; Jitendra Gupta; Nawin Kumar; Gaurab Mitra; Jean-François Saint-Sauveur; Siju Seena; Manica Balasegaram; Fernando Parreño; Krishna Pandey
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

9.  The new pyrazolyltetrazole derivative MSN20 is effective via oral delivery against cutaneous leishmaniasis.

Authors:  Viviane Dos Santos Faiões; Maurício Silva Dos Santos; Alice Maria Rolim Bernardino; Edézio Ferreira Cunha-Júnior; Marilene Marcuzzo do Canto Cavalheiro; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

10.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.